Fifteen years of experience in predictive testing for Huntington disease at a single testing center in Victoria, Australia

Genetics in Medicine

Volumn 8, Issue 11, 2006, Pages 673-680

  Trembath, M Kaye ^a   Tassicker, Roslyn J ^b   Collins, Veronica R ^a   Mansie, Sue ^b   Sheffield, Leslie J ^b   Delatycki, Martin B ^a  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b Genetic Health Services Victoria   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; GENETIC ANALYSIS; GENETIC PROCEDURES; HIGH RISK PATIENT; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; PREDICTION; RISK ASSESSMENT; SEX DIFFERENCE;

ADOLESCENT; ADOPTION; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CHILD; FAMILY HEALTH; FEMALE; GENETIC SCREENING; HUMANS; HUNTINGTON DISEASE; LINKAGE (GENETICS); MALE; MIDDLE AGED; PREGNANCY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33751086167     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gim.0000245633.97952.f1     Document Type: Article

References (49)

1. Hayden M. Huntington's chorea. New York: Springer; 1981.
2. Harper P. Huntington's disease. London: WB Saunders; 1991.
3. Gusella JF, Wexler NS, Conneally PM, Naylor SL, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983;306:234-238.
4. World Federation of Neurology: Research Committee. Research Group on Huntington's chorea. Ethical issues policy statement on Huntington's disease molecular genetics predictive test. J Neurol Sci 1989;94:327-332.
5. Nasioulas S, Sheffield L, Mansie S, Forrest S. Modified method for the detection of the CAG repeat expansion in Huntington's disease and application to a predictive testing protocol. Mol Diagn 1997;2:53-59.
6. Mansie S, Sheffield L, Forrest S, Chiu E, et al. Selection for presymptomatic testing for Huntington's disease: who decides? A reply from the Victorian Clin Genet Service, Murdoch Institute, Melbourne, Australia. J Med Genet 1996;33:1051-1052.
7. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
8. Tassicker RJ. Psychodynamic theory and counseling in predictive testing for Huntington's disease. J Genet Couns 2005;14:99-107.
9. Lathrop GM, Laloul JM, Julier C, Ott J. Multilocus linkage analysis in humans: detection of linkage and estimation of recombination. Am J Hum Genet 1985;37:482-498.
10. Potter NT, Spector EB, Prior TW. Technical standards and guidelines for Huntington disease testing. Genet Med 2004;6:61-65.
11. Australian Bureau of Statistics 3218.0 2003-2004 regional population growth, Australia and New Zealand. Preliminary local government area (LGA) populations (at 30 June 2004). Available at: http://www.abs.gov.au/. Accessed August 17, 2005.
12. Harper PS, Lim C, Craufurd D. Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium. J Med Genet 2000;37:567-571.
13. Goizet C, Lesca G, Durr A. Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias. Neurology 2002;59:1330-1336.
14. Creighton S, Almqvist EW, MacGregor D, Fernandez B, et al. Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clin Genet 2003;63:462-475.
15. Maat-Kievit A, Vegter-van der Vlis M, Zoeteweij M, Losekoot M, et al. Paradox of a better test for Huntington's disease. J Neurol Neurosurg Psychiatry 2000;69:579-583.
16. Laccone F, Christian W. A recurrent expansion of a maternal allele with 36 CAG repeats causes Huntington disease in two sisters. Am J Hum Genet 2000;66:1145-1148.
17. Craufurd D, Tyler A. Predictive testing for Huntington's disease: protocol of the UK Huntington's Prediction Consortium. J Med Genet 1992;29:915-918.
18. Bloch M, Fahy M, Fox S, Hayden MR. Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet 1989;32:217-224.
19. Holloway S, Mennie M, Crosbie A, Smith B, et al. Predictive testing for Huntington disease: social characteristics and knowledge of applicants, attitudes to the test procedure and decisions made after testing. Clin Genet 1994;46:175-180.
20. Taylor S. Gender differences in attitudes among those at risk for Huntington's disease. Genet Test 2005;9:152-157.
21. Taylor SD. Demand for predictive genetic testing for Huntington's disease in Australia, 1987 to 1993. Med J Aust 1994;161:351, 354-355.
22. Laccone F, Engel U, Holinski-Feder E, Weigell-Weber M, et al. DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland. Neurology 1999;53:801-806.
23. Kromberg JG, Krause A, Spurdle AB, Temlett JA, et al. Utilisation of predictive, prenatal and diagnostic testing for Huntington's disease in Johannesburg. S Afr Med J 1999;89:774-778.
24. Visintainer CL, Matthias-Hagen V, Nance MA. Anonymous predictive testing for Huntington's disease in the United States. Genet Test 2001;5:213-218.
25. Markel DS, Young AB, Penney JB. At-risk persons' attitudes toward presymptomatic and prenatal testing of Huntington's disease in Michigan. Am J Med Genet 1987;26:295-305.
26. Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Cassiman JJ, et al. Psychological functioning before predictive testing for Huntington's disease: the role of the parental disease, risk perception, and subjective proximity of the disease. J Med Genet 1999;36:897-905.
27. McCusker EA, Casse RF, Graham SJ, Williams DB, et al. Prevalence of Huntington disease in New South Wales in 1996. Med J Aust 2000;173:187-190.
28. Snell RG, MacMillan JC, Cheadle JP, Fenton I, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993;4:393-397.
29. Andrew SE, Goldberg YP, Kremer B, Telenius H, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993;4:398-403.
30. Duyao M, Ambrose C, Myers R, Novelletto A, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 1993;4:387-392.
31. Merritt AD, Conneally PM, Rahman NF, Drew AL. Juvenile Huntington's chorea. In: Barbeau A, Brunette JR, editors. Progress in neurogenetics. Amsterdam: Excerpta Medica; 1969:645-650.
32. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-277.
33. Kessler S. Forgotten person in the Huntington disease family. Am J Med Genet 1993;48:145-150.
34. Benjamin CM, Adam S, Wiggins S, Theilmann JL, et al. Proceed with care: direct predictive testing for Huntington disease. Am J Hum Genet 1994;55:606-617.
35. Rosenblatt A, Brinkman RR, Liang KY, Almqvist EW, et al. Familial influence on age of onset among siblings with Huntington disease. Am J Med Genet 2001;105:399-403.
36. Wexler NS, Lorimer J, Porter J, Gomez F, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 2004;101:3498-3503.
37. Rubinsztein DC, Leggo J, Coles R, Almqvist E, et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 1996;59:16-22.
38. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997;60:1202-1210.
39. Harper PS, Newcombe RG. Age at onset and life table risks in genetic counselling for Huntington's disease. J Med Genet 1992;29:239-242.
40. Bonke B, Tibben A, Lindhout D, Clarke AJ, et al. Genetic risk estimation by health-care professionals. Med J Aust 2005;182:116-118.
41. Evers-Kiebooms G, Swerts A, Cassiman JJ, Van den Berghe H. The motivation of at-risk individuals and their partners in deciding for or against predictive testing for Huntington's disease. Clin Genet 1989;35:29-40.
42. Quaid KA, Morris M. Reluctance to undergo predictive testing: the case of Huntington disease. Am J Med Genet 1993;45:41-45.
43. van der Steenstraten IM, Tibben A, Roos RA, van de Kamp JJ, et al. Predictive testing for Huntington disease: nonparticipants compared with participants in the Dutch program. Am J Hum Genet 1994;55:618-625.
44. Binedell J, Soldan JR, Harper PS. Predictive testing for Huntington's disease: I. Predictors of uptake in South Wales. Clin Genet 1998;54:477-488.
45. Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Cloostermans T, et al. Nonparticipation in predictive testing for Huntington's Disease: individual decision-making, personality and avoidant behaviour in the family. Eur J Hum Genet 1997;5:351-363.
46. Benjamin CM, Lashwood A. United Kingdom experience with presymptomatic testing of individuals at 25% risk for Huntington's disease. Clin Genet 2000;58:41-49.
47. Lindblad AN. To test or not to test: an ethical conflict with presymptomatic testing of individuals at 25% risk for Huntington's disorder. Clin Genet 2001;60:442-446.
48. Maat-Kievit A, Vegter-Van Der Vlis M, Zoeteweij M, Losekoot M, et al. Predictive testing of 25 percent at-risk individuals for Huntington disease (1987-1997). Am J Med Genet 1999;88:662-668.
49. Mandich P, Jacopini G, Di Maria E, Sabbadini G, et al. Predictive testing for Huntington's disease: ten years' experience in two Italian centres. Ital J Neurol Sci 1998;19:68-74.